Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs
2011

Making More Exosomes for Heart Treatment

Sample size: 10 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chen Tian Sheng, Arslan Fatih, Yin Yijun, Tan Soon Sim, Lai Ruenn Chai, Choo Andre Boon Hwa, Padmanabhan Jayanthi, Lee Chuen Neng, de Kleijn Dominique PV, Lim Sai Kiang

Primary Institution: Institute of Medical Biology, A*STAR

Hypothesis

Can MYC immortalization of hESC-derived MSCs allow for continuous production of therapeutic exosomes without compromising their efficacy?

Conclusion

MYC transformation allows for an infinite supply of cells to produce therapeutic exosomes, which can reduce heart damage in mice.

Supporting Evidence

  • MYC-transformed MSCs maintained the ability to produce therapeutic exosomes.
  • Exosomes from MYC-transformed MSCs significantly reduced infarct size in a mouse model.
  • The transformation allowed for faster cell growth and reduced production costs.

Takeaway

Scientists found a way to make more tiny helpers called exosomes that can protect the heart, by changing some cells so they never get old.

Methodology

The study involved transfecting hESC-derived MSCs with a MYC gene and analyzing the transformed cells for various characteristics and their ability to produce exosomes.

Potential Biases

Potential risks associated with the use of lentiviral vectors for cell transformation.

Limitations

The transformed cells lost the ability to undergo adipogenic differentiation, which is a key characteristic of MSCs.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1479-5876-9-47

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication